Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of “Buy” from Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have been given an average recommendation of “Buy” by the ten analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $16.5556.

A number of research analysts have commented on the stock. Wall Street Zen cut shares of Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Finally, Truist Financial began coverage on Inventiva in a research report on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price on the stock.

Institutional Trading of Inventiva

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Paradigm Biocapital Advisors LP acquired a new position in Inventiva in the 4th quarter valued at about $18,600,000. ADAR1 Capital Management LLC acquired a new position in Inventiva in the 4th quarter valued at about $12,601,000. UBS Group AG grew its position in Inventiva by 28,881.6% in the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after acquiring an additional 2,634,580 shares in the last quarter. SymBiosis Capital Partners LLC acquired a new position in Inventiva in the 4th quarter valued at about $12,090,000. Finally, Millennium Management LLC grew its position in Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after acquiring an additional 2,540,540 shares in the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Trading Down 1.7%

Shares of Inventiva stock opened at $3.51 on Tuesday. The stock has a 50 day moving average of $4.84 and a 200 day moving average of $5.36. Inventiva has a fifty-two week low of $2.85 and a fifty-two week high of $7.98.

Inventiva (NASDAQ:IVA) last posted its earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.01 million for the quarter. Research analysts predict that Inventiva will post -0.79 earnings per share for the current year.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.